Trending Topic

Pyoderma gangrenosum
6 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Pyoderma gangrenosum (PG) is a rare, painful and complex autoimmune skin condition that can present significant diagnostic and treatment challenges.1   To provide expert insights into this challenging disease, we spoke with Dr Benjamin Kaffenberger, a dermatologist at The Ohio State University (Columbus, OH, USA) specializing in the management of complex medical dermatologic conditions. Q. […]

touchLearning Activities

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to welcome Dr Benjamin Kaffenberger, Associate Professor of Dermatology at The Ohio State University Wexner Medical Center, to the touchDERMATOLOGY Expert Faculty. A leading expert in complex skin conditions such as pyoderma gangrenosum, DRESS syndrome, and SJS/TEN, Kaffenberger brings extensive clinical and research experience in drug reactions, wound care, and hospital dermatology.

Mark CompleteCompleted
BookmarkBookmarked

Vilobelimab, a monoclonal anti-C5a antibody, is emerging as a promising treatment for pyoderma gangrenosum (PG), a rare and chronic autoimmune skin disorder characterized by painful ulcerations. With no approved therapies in the USA or Europe, there remains a significant unmet need for effective treatment.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

With a career that spans continents, Prof. Dedee Murrell stands out as a global leader in dermatology and a passionate advocate for women in medicine. In this episode, we sit down together to explore her inspiring journey—from her early years in the UK and medical training in the USA to pioneering therapies for some of dermatology’s rarest and underserved conditions in Australia. We also reflect on her recent MDS Lifetime Achievement Award and discuss the value of mentorship, strategies for advancing a career in dermatology and academic medicine, and how to stay at the cutting edge of medical innovation.

Mark CompleteCompleted
BookmarkBookmarked

We are delighted to announce that Professor Luis FC Ensina has joined the Expert Faculty of touchDERMATOLOGY. A distinguished allergologist, Professor Ensina is renowned for his expertise in urticaria, drug allergies and angioedema. His extensive contributions to clinical care, research ...

Mark CompleteCompleted
BookmarkBookmarked

Atopic dermatitis (AD) is a chronic inflammatory skin condition affecting approximately 10–30% of children worldwide. Early-onset AD, which often emerges by age two, is associated with a higher risk of developing other allergic diseases such as asthma and food allergies. Beyond its physical burden, AD significantly impacts patients and their families, contributing to sleep disturbances, emotional distress, financial burdens, and social challenges.

Mark CompleteCompleted
BookmarkBookmarked

Briquilimab, an anti-c-Kit monoclonal antibody, is being investigated for its ability to selectively deplete mast cells and alleviate the symptoms of CSU. At this year’s American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress (San Diego, CA, USA; 28 February–3 March 2025), the initial results from BEACON (ClinicalTrials.gov identifier: NCT06162728), a phase Ib/IIa dose-escalation study of briquilimab in adults with CSU, were presented.3,4

Mark CompleteCompleted
BookmarkBookmarked

At this year’s American Academy of Allergy, Asthma and Immunology (AAAAI)/ World Allergy Organization (WAO) Joint Congress, findings from the pooled analysis of two phase III trials (LIBERTY-CSU CUPID Study A and Study C; ClinicalTrials.gov identifier: NCT04180488) investigating dupilumab in omalizumab-naïve patients with chronic spontaneous urticaria (CSU) were presented.

Mark CompleteCompleted
BookmarkBookmarked

Current treatment options for flares of symptomatic oral lichen planus primarily include topical corticosteroids as the first-line therapy. Second- and third-line treatments range from topical calcineurin inhibitors to systemic corticosteroids, systemic retinoids and topical or systemic immunomodulators.5

18 mins
Sponsored Content

Join experts Lisa Weibel, Amy Paller, and Eulàlia Baselga as they investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD.

Mark CompleteCompleted
BookmarkBookmarked

As 2025 unfolds, the field of dermatology is set for some significant advancements. To get a glimpse of what’s ahead, we turned to our esteemed Expert Faculty members, who shared their expert insights on what they think will be the key innovations shaping this year. From the most exciting trends of 2024 that are gaining momentum to the next breakthroughs poised to redefine patient care, here’s what they had to say.

Mark CompleteCompleted
BookmarkBookmarked

A first-in-human trial suggests ET-02 could be a promising novel topical treatment for androgenic alopecia. Participants using the 5% ET-02 solution saw a six-fold increase in non-vellus hair count within five weeks. Mechanism of Action ET-02 (Eirion Therapeutics Inc.) is a ...

43 mins
Sponsored Content

Watch leading experts discuss the pathophysiology of AD, PN, and CSU, and the concepts of AD remission and disease modification.

Mark CompleteCompleted
BookmarkBookmarked

Join us as we reveal the content that made the greatest impact in 2024. From expert Q&As and engaging podcasts, to conference highlights, news stories, and a wealth of medical education, this year’s content has been created to inspire and support your daily practice while enhancing patient outcomes.

24 mins
Sponsored Content
touchEXPERT BRIEFING
For HCPs in: Global excluding Brazil, Italy, UK, US, and Spain

Watch leading experts discuss updates in the treatment of chronic spontaneous urticaria (CSU), based on data presented at EAACI 2024.

Mark CompleteCompleted
BookmarkBookmarked

In an encouraging development for children with severe atopic dermatitis (AD), dupilumab, an interleukin-4 (IL-4) receptor alpha antagonist, has shown evidence of improving height outcomes. According to new findings presented by Prof. Alan Irvine (Trinity College Dublin, Ireland) at the 2024 ...

Mark CompleteCompleted
BookmarkBookmarked

A new study, presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress, reveals the potential of semaglutide, a GLP-1 receptor agonist, in treating hidradenitis suppurativa (HS). This research suggests semaglutide, already approved for obesity and diabetes treatment, may reduce HS flare-ups and improve quality of life in obese patients. Learn how this promising therapy could mark a breakthrough in managing this chronic skin condition. Read the full study published in the British Journal of Dermatology."

Mark CompleteCompleted
BookmarkBookmarked

We are deeply saddened to learn of the passing of Prof. Marcus Maurer, a highly esteemed expert who contributed significantly to touchDERMATOLOGY. Our hearts and deepest sympathies are with his family and close friends during this difficult time. His guidance, ...

Mark CompleteCompleted
BookmarkBookmarked

The FDA has approved nemolizumab-ilto (Nemluvio; Galderma) for treating prurigo nodularis, a chronic skin condition characterized by intensely itchy nodules. Nemolizumab is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31, a neuroimmune cytokine that drives multiple disease mechanisms in prurigo nodularis

Load More...
touchDERMATOLOGY touchDERMATOLOGY

Register Now!

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

  • Save your progress for video
  • Keep track of your CME credits
  • Add personalised learning notes
  • Receive updates from course leaders and faculty
  • Be the first to hear about new and exciting interactive learning opportunities
Close Popup